Higher sPD-L1 levels were observed in patients with metastatic than non-metastatic clear cell renal cell carcinoma (87), and sPD-L1 levels were significantly elevated in patients with muscle-invasive and metastatic urinary bladder cancer (88). Here, SPDL1 is linked to clear cell renal carcinoma.